1. Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes 1990;39:1315.
2. Barnett AH, Eff C, Leslie RD, et al. Diabetes in identical twins: a study of 200 pairs. Diabetologia 1981;20:87.
3. Velho G, Robert JJ. Maturity-onset diabetes of the young (MODY): genetic and clinical characteristics. Horm Res 2002;57(suppl 1):29.
4. Taylor SI, Kadowaki T, Kadowaki H, et al. Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 1990;13:257.
5. Maassen JA. Mitochondrial diabetes: pathophysiology, clinical presentation, and genetic analysis. Am J Med Genet 2002;115:66.
6. Collins FS. Positional cloning: let’s not call it reverse anymore. Nat Genet 1992;1:3.
7. Ott J. Analysis of human genetic linkage. Baltimore, MD: John Hopkins University Press, 1991.
8. Blackwelder WC, Elston RC. Power and robustness of sib pair linkage tests and extension to larger sibships. Comm Stat Theory Method 1982;11:449.
9. Orita M, Suzuki Y, Sekiya T, et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874.
10. Myers RM, Lumelsky N, Lerman LS, et al. Detection of single base substitutions in total genomic DNA. Nature 1985;313:495.
11. Henco K, Harders J, Wiese U, et al. Temperature gradient gel electrophoresis (TGGE) for the detection of polymorphic DNA and RNA. Methods Mol Biol 1994;31:211.
12. Keen J, Lester D, Inglehearn C, et al. Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels. Trends Genet 1991; 7:5.
13. Celi FS, Cohen MM, Antonarakis SE, et al. Determination of gene dosage by a quantitative adaptation of the polymerase chain reaction (gd-PCR): rapid detection of deletions and duplications of gene sequences. Genomics 1994;21:304.
14. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002;32:3.
15. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000;113:3.
16. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002;113(suppl 6A):3.
17. Prochazka M, Lillioja S, Tait JF, et al. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993;42:514.
18. Randle PJ, Garland PB, Newsholme EA, et al. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann NY Acad Sci 1965;131:324.
19. Baier LJ, Sacchettini JC, Knowler WC, et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995;95:1281.
20. Hayakawa T, Nagai Y, Nohara E, et al. Variation of the fatty acid binding protein 2 gene is not associated with obesity and insulin resistance in Japanese subjects. Metabolism 1999;48:655.
21. Galluzzi JR, Cupples LA, Meigs JB, et al. Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. Diabetes Care 2001;24:1161.
22. Sipilainen R, Uusitupa M, Heikkinen S, et al. Variants in the human intestinal fatty acid binding protein 2 gene in obese subjects. J Clin Endocrinol Metab 1997;82:2629.
23. Hegele RA, Young TK, Connelly PW. Are Canadian Inuit at increased genetic risk for coronary heart disease? J Mol Med 1997;75: 364.
24. Yamada K, Yuan X, Ishiyama S, et al. Association between Ala54Thr substitution of the fatty acid–binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997;40:706.
25. Brown MD, Shuldiner AR, Ferrell RE, et al. FABP2 genotype is associated with insulin sensitivity in older women. Metabolism 2001; 50:1102.
26. Ito K, Nakatani K, Fujii M, et al. Codon 54 polymorphism of the fatty acid binding protein gene and insulin resistance in the Japanese population. Diabet Med 1999;16:119.
27. Rissanen J, Pihlajamaki J, Heikkinen S, et al. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes 1997;46:711.
28. Lei HH, Coresh J, Shuldiner AR, et al. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 1999;48:1868.
29. Baier LJ, Bogardus C, Sacchettini JC. A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem 1996;271:10892.
30. Agren JJ, Valve R, Vidgren H, et al. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene. Arterioscler Thromb Vasc Biol 1998;18:1606.
31. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667.
32. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337.
33. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:782.
34. Hansen L, Hansen T, Vestergaard H, et al. A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 1995;4:1313.
35. Xia J, Scherer SW, Cohen PT, et al. A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 1998; 47:1519.
36. Maegawa H, Shi K, Hidaka H, et al. The 3′-untranslated region polymorphism of the gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in the type 2 diabetic Japanese population. Diabetes 1999;48:1469.
37. Hegele RA, Harris SB, Zinman B, et al. Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 1998;83:3980.
38. Prochazka M, Mochizuki H, Baier LJ, et al. Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its major role in insulin resistance in Pima Indians. Diabetologia 1995;38:461.
39. Kane C, Shepherd RM, Squires PE, et al. Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med 1996;2:1344.
40. Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996;5:1809.
41. Thomas PM, Cote GJ, Wohllk N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426.
42. Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47:598.
43. Inoue H, Ferrer J, Welling CM, et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996;45:825.
44. Hani EH, Clement K, Velho G, et al. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997;46:688.
45. Hansen L, Echwald SM, Hansen T, et al. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997;46: 508.
46. Inoue H, Ferrer J, Warren-Perry M, et al. Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes 1997;46:502.
47. Sakura H, Wat N, Horton V, et al. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in white Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 1996;39: 1233.
48. Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/ BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 1998;41:1511.
49. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003;52:568.
50. Tschritter O, Stumvoll M, Machicao F, et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 2002;51:2854.
51. Schwanstecher C, Neugebauer B, Schulz M, et al. The common single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancreatic beta-cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. Diabetes 2002;51(suppl 3):363.
52. Neel JV. The thrifty genotype revisited. In: Kobberling J, Tattersall R, eds. The genetics of diabetes mellitus: proceedings of the Serono Symposium. London: Academic, 1982:283–293.
53. Walston J, Silver K, Bogardus C, et al. Time of onset of non–insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333:343.
54. Widen E, Lehto M, Kanninen T, et al. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333:348.
55. Silver K, Walston J, Wang Y, et al. Molecular scanning for mutations in the beta 3-adrenergic receptor gene in Nauruans with obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4155.
56. Kadowaki H, Yasuda K, Iwamoto K, et al. A mutation in the beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995; 215:555.
57. Biery AJ, Ebbesson SO, Shuldiner AR, et al. The beta(3)-adrenergic receptor TRP64ARG polymorphism and obesity in Alaskan Eskimos. Int J Obes Relat Metab Disord 1997;21:1176.
58. Clement K, Vaisse C, Manning BS, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352.
59. Shuldiner AR, Sabra M. Trp64Arg beta3-adrenoceptor: when does a candidate gene become a disease-susceptibility gene? Obes Res 2001; 9:806.
60. Mitchell BD, Blangero J, Comuzzie AG, et al. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans. J Clin Invest 1998;101:584.
61. Garcia-Rubi E, Starling RD, Tchernof A, et al. Trp64Arg variant of the beta3-adrenoceptor and insulin resistance in obese postmenopausal women. J Clin Endocrinol Metab 1998;83:4002.
62. Walston J, Silver K, Hilfiker H, et al. Insulin response to glucose is lower in individuals homozygous for the Arg 64 variant of the beta-3-adrenergic receptor. J Clin Endocrinol Metab 2000;85:4019.
63. Perfetti R, Hui H, Chamie K, et al. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity. J Mol Endocrinol 2001;27:133.
64. Oizumi T, Daimon M, Saitoh T, et al. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 2001;24:1579.
65. Ghosh S, Langefeld CD, Ally D, et al. The W64R variant of the beta3-adrenergic receptor is not associated with type II diabetes or obesity in a large Finnish sample. Diabetologia 1999;42:238.
66. Gagnon J, Mauriege P, Roy S, et al. The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohorts. J Clin Invest 1996;98:2086.
67. Oeveren van-Dybicz AM, Vonkeman HE, Bon MA, et al. Beta 3-adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian population. Diabetes Obes Metab 2001;3:47.
68. Pulkkinen A, Kareinen A, Saarinen L, et al. The codon 64 polymorphism of the beta3-adrenergic receptor gene is not associated with coronary heart disease or insulin resistance in nondiabetic subjects and non–insulin-dependent diabetic patients. Metabolism 1999;48: 853.
69. Kurokawa N, Nakai K, Kameo S, et al. Association of BMI with the beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res 2001;9:741.
70. Allison DB, Heo M, Faith MS, et al. Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. Int J Obes Relat Metab Disord 1998;22:559.
71. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998;83:2441.
72. Ishii T, Hirose H, Kawai T, et al. Effects of intestinal fatty acid-binding protein gene Ala54Thr polymorphism and beta3-adrenergic receptor gene Trp64Arg polymorphism on insulin resistance and fasting plasma glucose in young to older Japanese men. Metabolism 2001;50:1301.
73. Clement K, Ruiz J, Cassard-Doulcier AM, et al. Additive effect of A→G (–3826) variant of the uncoupling protein gene and the Trp64Arg mutation of the beta 3-adrenergic receptor gene on weight gain in morbid obesity. Int J Obes Relat Metab Disord 1996;20:1062.
74. Dionne IJ, Turner AN, Tchernof A, et al. Identification of an interactive effect of beta3- and alpha2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women. Diabetes 2001;50:91.
75. Hsueh WC, Cole SA, Shuldiner AR, et al. Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity. Diabetes Care 2001;24:672.
76. Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002;51:880.
77. Snitker S, Odeleye OE, Hellmer J, et al. No effect of the Trp64Arg beta 3-adrenoceptor variant on in vivo lipolysis in subcutaneous adipose tissue. Diabetologia 1997;40:838.
78. Tataranni PA, Pratley R, Shuldiner A, et al. Beta 3-adrenergic receptor gene variant and lipid metabolism in Pima Indians. Diabetologia 1997;40:123.
79. Li LS, Lonnqvist F, Luthman H, et al. Phenotypic characterization of the Trp64Arg polymorphism in the beta 3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 1996;39:857.
80. Hoffstedt J, Poirier O, Thorne A, et al. Polymorphism of the human beta3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function. Diabetes 1999;48:203.
81. Umekawa T, Yoshida T, Sakane N, et al. Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes. Diabetes 1999; 48:117.
82. Candelore MR, Deng L, Tota LM, et al. Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology 1996;137:2638.
83. Pietri-Rouxel F, St. John Manning B, Gros J, et al. The biochemical effect of the naturally occurring Trp64→Arg mutation on human beta3-adrenoceptor activity. Eur J Biochem 1997;247:1174.
84. McLenithan J, Xu AH, Pray J, et al. W64R is a naturally occurring dominant negative mutation in the beta3-adrenergic receptor. Diabetes 2001;50(suppl 2):A332.
85. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270.
86. Celi FS, Shuldiner AR. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. Curr Diab Rep 2002;2:179.
87. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284.
88. Masugi J, Tamori Y, Mori H, et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178.
89. Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212.
90. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891.
91. Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 2001;50:886.
92. Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002;51:2581.
93. Hegele RA, Cao H, Harris SB, et al. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000;85:2014.
94. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002;51:2341.
95. Sramkova D, Kunesova M, Hainer V. Is a Pro12Ala polymorphism of the PPARgamma2 gene related to obesity and type 2 diabetes mellitus in the Czech population? Ann NY Acad Sci 2002;967:265.
96. Hasstedt SJ, Ren QF, Teng K, et al. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001;86:536.
97. Lei HH, Chen MH, Yang WS, et al. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000;49:1267.
98. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76.
99. Gonzalez Sanchez JL, Serrano RM, Fernandez PC, et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002;147:495.
100. Frederiksen L, Brodbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002;87:3989.
101. Stumvoll M, Wahl HG, Loblein K, et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001; 50:876.
102. Jacob S, Stumvoll M, Becker R, et al. The PPARgamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000;32:413.
103. Koch M, Rett K, Maerker E, et al. The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999;42:758.
104. Mori Y, Kim-Motoyama H, Katakura T, et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195.
105. Mancini FP, Vaccaro O, Sabatino L, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999;48:1466.
106. Oh EY, Min KM, Chung JH. Significance of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801.
107. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47: 1806.
108. Meirhaeghe A, Fajas L, Helbecque N, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non–insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195.
109. Cole SA, Mitchell BD, Hsueh WC, et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000;24:522.
110. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50:686.
111. Ek J, Urhammer SA, Sorensen TI, et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999;42:892.
112. Nicklas BJ, van Rossum EF, Berman DM, et al. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001;50:2172.
113. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536.
114. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325.
115. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51:2306.
116. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002;51:37.
117. Garcia-Rubi E, Calles-Escandon J. Insulin resistance and type 2 diabetes mellitus: its relationship with the beta 3-adrenergic receptor. Arch Med Res 1999;30:459.
118. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 1999;23:323.
119. Dupont S, Vionnet N, Chevre JC, et al. No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/ NEUROD1 and PAX4 in type II diabetes in France. Diabetologia 1999;42:480.
120. Utsunomiya N, Ohagi S, Sanke T, et al. Organization of the human carboxypeptidase E gene and molecular scanning for mutations in Japanese subjects with NIDDM or obesity. Diabetologia 1998;41:701.
121. Yagui K, Shimada F, Mimura M, et al. A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro. Diabetologia 1998;41:1024.
122. Rau H, Braun J, Donner H, et al. The codon 17 polymorphism of the CTLA4 gene in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:653.
123. Ristow M, Giannakidou E, Hebinck J, et al. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich’s ataxia) gene. Diabetes 1998;47:851.
124. Dalgaard LT, Hansen T, Urhammer SA, et al. Intermediate expansions of a GAA repeat in the frataxin gene are not associated with type 2 diabetes or altered glucose-induced beta-cell function in Danish Caucasians. Diabetes 1999;48:914.
125. Hart LM, Ruige JB, Dekker JM, et al. Altered beta-cell characteristics in impaired glucose tolerant carriers of a GAA trinucleotide repeat polymorphism in the frataxin gene. Diabetes 1999;48:924.
126. Kubota A, Yamada Y, Hayami T, et al. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996;45:1701.
127. Almind K, Ambye L, Urhammer SA, et al. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 1998;41:1194.
128. Velho G, Froguel P. Genetic determinants of non–insulin-dependent diabetes mellitus: strategies and recent results. Diabetes Metab 1997; 23:7.
129. Huang CN, Lee KC, Wu HP, et al. Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan. Pancreas 1999;18:151.
130. Lepretre F, Vionnet N, Budhan S, et al. Genetic studies of polymorphisms in ten non–insulin-dependent diabetes mellitus candidate genes in Tamil Indians from Pondichery. Diabetes Metab 1998;24: 244.
131. Tanizawa Y, Riggs AC, Elbein SC, et al. Human glucagon-like peptide-1 receptor gene in NIDDM: identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes 1994;43: 752.
132. Yagi T, Nishi S, Hinata S, et al. A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet Med 1996;13:902.
133. Janssen RC, Bogardus C, Takeda J, et al. Linkage analysis of acute insulin secretion with GLUT2 and glucokinase in Pima Indians and the identification of a missense mutation in GLUT2. Diabetes 1994;43:558.
134. Tanizawa Y, Riggs AC, Chiu KC, et al. Variability of the pancreatic islet beta cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. Diabetologia 1994;37:420.
135. Shimada F, Makino H, Iwaoka H, et al. Identification of two novel amino acid polymorphisms in beta-cell/liver (GLUT2) glucose transporter in Japanese subjects. Diabetologia 1995;38:211.
136. Matsutani A, Koranyi L, Cox N, et al. Polymorphisms of GLUT2 and GLUT4 genes: use in evaluation of genetic susceptibility to NIDDM in blacks. Diabetes 1990;39:1534.
137. Baroni MG, Oelbaum RS, Pozzilli P, et al. Polymorphisms at the GLUT1 (HepG2) and GLUT4 (muscle/adipocyte) glucose transporter genes and non-insulin-dependent diabetes mellitus (NIDDM). Hum Genet 1992;88:557.
138. Kusari J, Verma US, Buse JB, et al. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non–insulin-dependent diabetes mellitus. J Clin Invest 1991;88:1323.
139. Choi WH, O’Rahilly S, Buse JB, et al. Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes 1991;40:1712.
140. Groop LC, Kankuri M, Schalin-Jantti C, et al. Association between polymorphism of the glycogen synthase gene and non–insulin- dependent diabetes mellitus. N Engl J Med 1993;328:10.
141. Shimomura H, Sanke T, Ueda K, et al. A missense mutation of the muscle glycogen synthase gene (M416V) is associated with insulin resistance in the Japanese population. Diabetologia 1997;40:947.
142. Rissanen J, Pihlajamaki J, Heikkinen S, et al. New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland. Diabetologia 1997;40:1313.
143. Vidal-Puig A, Printz RL, Stratton IM, et al. Analysis of the hexokinase II gene in subjects with insulin resistance and NIDDM and detection of a Gln142→His substitution. Diabetes 1995;44:340.
144. Echwald SM, Bjorbaek C, Hansen T, et al. Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. Diabetes 1995;44:347.
145. Olansky L, Janssen R, Welling C, et al. Variability of the insulin gene in American blacks with NIDDM. Analysis by single-strand conformational polymorphisms. Diabetes 1992;41:742.
146. Pugliese A, Miceli D. The insulin gene in diabetes. Diabetes Metab Res Rev 2002;18:13.
147. Sakagashira S, Sanke T, Hanabusa T, et al. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996;45:1279.
148. Yamada K, Yuan X, Ishiyama S, et al. Glucose tolerance in Japanese subjects with S20G mutation of the amylin gene. Diabetologia 1998; 41:125.
149. Chuang LM, Lee KC, Huang CN, et al. Role of S20G mutation of amylin gene in insulin secretion, insulin sensitivity, and type II diabetes mellitus in Taiwanese patients. Diabetologia 1998;41:1250.
150. Birch CL, Fagan LJ, Armstrong MJ, et al. The S20G islet-associated polypeptide gene mutation in familial NIDDM. Diabetologia 1997; 40:1113.
151. Shimomura H, Sanke T, Hanabusa T, et al. Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. Diabetes 2000;49:1597.
152. Barat-Houari M, Clement K, Vatin V, et al. Positional candidate gene analysis of Lim domain homeobox gene (Isl-1) on chromosome 5q11-q13 in a French morbidly obese population suggests indication for association with type 2 diabetes. Diabetes 2002;51:1640.
153. Wolford JK, Hanson RL, Bogardus C, et al. Analysis of the lamin A/C gene as a candidate for type II diabetes susceptibility in Pima Indians. Diabetologia 2001;44:779.
154. Baier LJ, Wiedrich C, Hanson RL, et al. Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women. Diabetes 1998;47:973.
155. Hansen T, Andersen CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997;46:494.
156. Frittitta L, Ercolino T, Bozzali M, et al. A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 2001;50:1952.
157. Pizzuti A, Frittitta L, Argiolas A, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999;48:1881.
158. Jaikaran ET, Marcon G, Levesque L, et al. Localisation of presenilin 2 in human and rodent pancreatic islet beta-cells; Met239Val presenilin 2 variant is not associated with diabetes in man. J Cell Sci 1999;112:2137.
159. Kalidas K, Dow E, Saker PJ, et al. Prohormone convertase 1 in obesity, gestational diabetes mellitus, and NIDDM: no evidence for a major susceptibility role. Diabetes 1998;47:287.
160. Ohagi S, Sakaguchi H, Sanke T, et al. Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Diabetes 1996;45:897.
161. Yoshida H, Ohagi S, Sanke T, et al. Association of the prohormone convertase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects. Diabetes 1995;44:389.
162. Permana PA, Kahn BB, Huppertz C, et al. Functional analyses of amino acid substitutions Arg883Ser and Asp905Tyr of protein phosphatase-1 G-subunit. Mol Genet Metab 2000;70:151.
163. Yuan X, Yamada K, Ishiyama-Shigemoto S, et al. Analysis of trinucleotide-repeat combination polymorphism at the rad gene in patients with type 2 diabetes mellitus. Metabolism 1999;48:173.
164. Sentinelli F, Romeo S, Arca M, et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002;51:860.
165. Wang H, Chu WS, Hemphill C, et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87:2520.
166. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002;51:863.
167. Varadi A, Lebel L, Hashim Y, et al. Sequence variants of the sarco (endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48). Diabetologia 1999;42:1240.
168. Goksel DL, Fischbach K, Duggirala R, et al. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet 1998;103:280.
169. Baier LJ, Dobberfuhl AM, Pratley RE, et al. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998;83:2993.
170. Baynes KC, Boucher BJ, Feskens EJ, et al. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997;40:344.
171. Hitman GA, Mannan N, McDermott MF, et al. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998;47:688.
172. Chiu KC, Chuang LM, Yoon C. The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet 2001;2:2.